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a b s t r a c t
Limited effectiveness data are available comparing live attenuated inﬂuenza vaccine (LAIV) to inactivated
inﬂuenza vaccine (TIV) among adults. To compare the incidence of inﬂuenza-like illness following immunization of adults with LAIV vs. TIV, we conducted a retrospective cohort analysis of active component U.S.
military personnel for the 2005–2006 and 2006–2007 inﬂuenza seasons. Recruits experienced a much
higher burden of disease compared to non-recruits, with crude incidence rates of inﬂuenza-like illness
2–16 times higher than non-recruits depending on the season and cohort. For both seasons, a slightly
greater protection from inﬂuenza-like illness was found for non-recruits who received TIV compared to
LAIV (adjusted incidence rate ratio, 1.17 (95% CI, 1.14–1.20) and 1.33 (95% CI, 1.30–1.36), 2005–2006 and
2006–2007 inﬂuenza seasons, respectively). However, for Army and Air Force recruits, LAIV was found
to provide signiﬁcantly greater protection from inﬂuenza-like illnesses compared to TIV, with adjusted
incidence rates of inﬂuenza-like illness 22–51% and 18–47% lower among LAIV compared to TIV recipients for the 2005–2006 and 2006–2007 inﬂuenza seasons, respectively. Possible reasons for differences
in recruit and non-recruit ﬁndings include differences in pre-existing inﬂuenza antibody levels, differing
respiratory disease burden, and/or unmeasured confounding. Consideration of these ﬁndings should be
made when developing inﬂuenza immunization policies.
© 2009 Elsevier Ltd. All rights reserved.

1. Introduction
A live attenuated inﬂuenza vaccine (LAIV) has been licensed
for use in children and adults in the U.S. since 2003. The vaccine, which is administered intranasally, represents the ﬁrst new
approach to inﬂuenza vaccines licensed since the development of
split virus vaccines. The injectable trivalent, inactivated inﬂuenza
vaccine (TIV) continues to be used regularly in the U.S. and remains
the only option for groups not eligible to receive LAIV. Several
studies have been conducted to evaluate the efﬁcacy and effectiveness of LAIV in comparison to both people receiving TIV and
unvaccinated individuals. However, the majority of these studies
were conducted among children. In children less than 5 years of
age and asthmatic children 6–17 years of age, LAIV was found to
have superior efﬁcacy and effectiveness in comparison to TIV [1–4].
A limited number of studies, mostly randomized trials or experimental challenge studies, have been conducted among adults.
Although both vaccines have been shown to have absolute effectiveness against inﬂuenza-like illness in adults, studies directly
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comparing LAIV to TIV found mixed results on which vaccine had
superior efﬁcacy in the prevention of culture-conﬁrmed inﬂuenza
[5–9].
Within the U.S. military population, inﬂuenza and other respiratory infections have historically caused signiﬁcant morbidity and
mortality [10–13]. Recruit settings, service on ships, and other military settings which require crowding have been associated with
outbreaks of inﬂuenza, occasionally despite high immunization
rates [14–17]. The U.S. military has been a strong proponent for
the development and use of inﬂuenza vaccines since the 1940s
[10]. Annual inﬂuenza immunization for the active force began
in the 1950s and total force (active and reserve components)
inﬂuenza immunization remains a mandatory yearly requirement
barring a contraindicating condition [10,18]. Continually since the
2003–2004 inﬂuenza season, military immunization policies have
called for preferential use of LAIV for all eligible service members, with TIV reserved for those not eligible to receive LAIV
[19–21]. Recommendations for preferential use of LAIV over TIV
originated from greater demand for inﬂuenza vaccine during the
2003–2004 season and the need to maintain adequate supplies of
TIV for high risk populations not eligible to receive LAIV [22,23].
Although policies emphasize the use of LAIV, there have not been
any investigations on the efﬁcacy or effectiveness of this vaccine
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in comparison to TIV among military service members. The few
population-based military studies that investigated inﬂuenza vaccine effectiveness were conducted among military basic trainees
assessing TIV only during the 2003–2004 season and TIV and LAIV
during the 2005–2006 season. These studies found very high vaccine effectiveness (92–94%) against laboratory conﬁrmed inﬂuenza
[24,25].
The U.S. military population provides a unique group to investigate and compare inﬂuenza vaccines, because it is primarily
comprised of healthy adults who are annually immunized against
inﬂuenza. In the general U.S. population, healthy young adults are
not considered at high risk for signiﬁcant inﬂuenza morbidity, so
they are not targeted for immunization. As a result, this group has
the lowest immunization rates compared to other age groups, making it difﬁcult to investigate and compare inﬂuenza vaccines in this
group outside of a clinical trial [26,27]. In order to evaluate how well
LAIV and TIV protect against inﬂuenza-like illness (ILI) among the
adult population and to better inform U.S. military inﬂuenza immunization policy, we conducted this analysis for the 2005–2006 and
2006–2007 inﬂuenza seasons.
2. Materials and methods
2.1. Study design
This was a retrospective cohort study. Two consecutive inﬂuenza
seasons, 2005–2006 and 2006–2007, were investigated. The
Defense Medical Surveillance System (DMSS) contains demographic, occupational, immunization, and medical encounter data
for U.S. military service members [28]. Using DMSS, we identiﬁed
the eligible cohorts for each year of the study. The cohorts consisted
of service members in the active component of the U.S. Army, Air
Force, Navy, or Marine Corps, who were stationed in the U.S. and
who had documentation of receiving only one dose of either LAIV
or TIV from 1 September to 30 April during the season of interest. Determination of which vaccine a service member receives is
typically not dependant on self-selection, but driven by service speciﬁc policies and vaccine ordering, availability of vaccines (early
in the season one vaccine type may be available before the other
type or shortages could affect vaccine selection by the clinic), and
pre-existing exclusions for one vaccine type (age, contraindicating
illnesses). To ensure that our study population consisted of service
members eligible to receive either vaccine, service members 50
years of age or older and those who were pregnant at the time of
immunization were excluded from the cohort.
Person-time at risk was calculated by summing the time from
14 days after inﬂuenza immunization to the end of the surveillance
period (30 April) or the occurrence of a right censoring event. Right
censoring events included overseas deployment, termination of
military service, or change in status from active to reserve or guard
component. Affected individuals were not considered “at risk” for
30 days after each ILI; hence, the 30 days after each ILI was excluded
from the person-time at risk.
2.2. Identiﬁcation of inﬂuenza-like illness
DMSS was used to identify ILIs among the study cohorts. An
ILI event was deﬁned as an outpatient or inpatient medical visit
which resulted in an ICD-9 diagnostic code (Table 1) consistent
with an ILI. The ICD-9 codes selected for this study were previously
shown to be associated with culture-conﬁrmed inﬂuenza illnesses
among the U.S. military population [29]. To be counted as an ILI
event, the medical encounter had to occur during the follow-up
period which began 14 days after immunization and ended on 30
April or the date of a right censoring event. Medical visits occur-
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Table 1
ICD-9-CM codes used to identify inﬂuenza-like illness.
ICD-9-CM code

Description

79.99
382.9
460.0
461.9
465.8
465.9
466.0
486.0
487.0
487.1
487.8
490.0
780.6
786.2

Viral infection, NOSa
Otitis media, NOSa
Nasopharyngitis, acute
Acute sinusitis, unspeciﬁed
Upper respiratory infection, other multiple sites
Upper respiratory infection, acute NOSa
Bronchitis and bronchiolitis, acute
Pneumonia, organism unspeciﬁed
Inﬂuenza with pneumonia
Inﬂuenza with other respiratory manifestations
Inﬂuenza with other manifestations
Bronchitis, not speciﬁed as acute or chronic
Fever
Cough

a

NOS: not otherwise speciﬁed.

ring within 30 days of a primary visit were considered the same ILI
event.
2.3. Statistical analysis
Three separate analytic plans were used for this study to address
possible bias due to changing inﬂuenza activity during the season
and timing of vaccine administration. The ﬁrst method, the “Continuous Cohort”, included the entire eligible cohort. People could
enter the study cohort at any point during the inﬂuenza season
when they received the inﬂuenza vaccine. The second method, the
“November Cohort”, included only people immunized during the
month of November. For these ﬁrst two methods, every new ILI
event (30 days window applied) was counted as an outcome. The
third method, the “Intense Cohort”, included only people immunized from 1 September to 14 days prior to the start of the intense
inﬂuenza period. Based on U.S. national data from the Centers for
Disease Control and Prevention (CDC), the intense inﬂuenza period
was deﬁned as the 8 weeks with the highest percentage of isolates testing positive for inﬂuenza surrounding the peak inﬂuenza
week (deﬁned as the week with the highest percentage of tests
positive for inﬂuenza) [30–32]. The intense inﬂuenza period was
deﬁned as 29 January 2006 through 01 April 2006 and 21 January
2007 through 24 March 2007 for the 2005–2006 and 2006–2007
inﬂuenza seasons, respectively. For the intense cohort, only the ﬁrst
ILI occurring during the intense inﬂuenza period was counted as an
outcome. Person-time was censored on the date of the ILI medical
visit.
For all analyses, recruits and non-recruits were analyzed separately due to differences in baseline risk of ILI and strong effect
modiﬁcation between recruit status and immunization received.
Recruit status was deﬁned at the time of immunization. In addition, recruits were stratiﬁed by service. Navy and Marine recruits
were almost entirely immunized with TIV, therefore comparisons between the two vaccines could not be made in these
populations. This was also seen for the Air Force recruit November cohort, which consisted mainly of LAIV recipients for the
2005–2006 inﬂuenza season and TIV recipients for the 2006–2007
season.
The incidence of ILI per 1000 person-years (PY) was calculated
for people who received either LAIV or TIV. The crude incidence
rate ratio (IRR) and 95% conﬁdence intervals (CI) were calculated
comparing the ILI incidence in the LAIV group vs. the TIV group.
In order to control for confounders, a Poisson regression model
was used to estimate the adjusted IRR and 95% CI. Conﬁdence
intervals that did not include 1.0 were considered statistically sig´ = 0.05 level of signiﬁcance. The model included
niﬁcant at an ␣
covariates that were considered a prior to be risk factors for
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Table 2
Demographic and service characteristics of the non-recruit and recruit cohorts by season and immunization group.
Characteristic

2005–2006 inﬂuenza season
Non-recruits

2006–2007 inﬂuenza season
Recruits

Non-recruits

Recruits

TIV

LAIV

TIV

LAIV

TIV

LAIV

TIV

LAIV

Total cohort (N)
Age (years)
17–19
20–29
30–39
40–49

565,165(%)

136,588(%)

49,990(%)

20,335(%)

372,117(%)

384,974(%)

30,420(%)

17,547(%)

5.5
56.8
27.7
10.1

9.0
54.2
27.5
9.3

49.1
49.4
1.5
<0.1

45.7
51.5
2.7
<0.1

5.6
57.1
27.4
10.0

7.6
56.5
26.7
9.1

46.7
50.7
2.4
0.2

43.3
51.7
4.6
0.4

Sex
Male

85.6

85.0

83.6

79.4

86.0

85.7

82.0

81.1

Race-ethnicity
White
Black
Hispanic
Other/unknown

63.9
17.5
9.8
8.9

66.5
17.1
8.8
7.7

68.0
12.2
10.0
9.9

68.6
15.2
9.6
6.7

64.2
16.4
10.1
9.5

65.4
17.6
9.2
7.8

71.7
14.8
6.6
7.0

69.6
15.6
9.1
5.8

Service
Army
Air Force
Marine Corps
Navy

34.1
35.7
9.9
20.3

61.6
35.0
1.0
2.4

29.9
23.0
21.3
25.8

77.7
21.7
0.6
0.0

26.8
32.0
14.5
26.8

53.9
32.7
7.3
6.1

35.8
42.1
12.3
9.8

81.6
16.8
0.2
1.4

Number of medical visits in previous year
0
11.5
<10
66.9
10–19
15.2
20+
6.4

9.0
68.3
16.0
6.7

99.8
0.2
<0.1
0.0

96.5
3.5
0.0
0.0

5.8
50.3
26.2
17.7

4.1
48.5
28.4
19.2

99.7
0.4
0.0
0.0

99.6
0.4
<0.1
<0.1

Ever hospitalized
Yes

a

19.6

N/A

N/A

19.2

19.2

N/A

N/A

Other immunization on same day
Yes
20.3

19.9

17.5

91.3

88.2

15.1

19.5

97.0

91.1

Other immunizations in previous 1–30 days
Yes
7.6

6.6

20.3

38.3

6.4

7.9

32.6

64.5

N/A

N/A

33.0

61.5

N/A

N/A

Flu vaccine given in previous inﬂuenza season
Yes
45.6
50.4

Percentages may not add up to 100% due to rounding. LAIV, live attenuated inﬂuenza vaccine; TIV, trivalent inﬂuenza vaccine.
a
Race-ethnicity was self-reported and categorized in the DMSS. “Other” included Asian/Paciﬁc Islander, American Indian/Alaska Native, and other.

inﬂuenza or vaccine selection and included sex, age at immunization, service component, race-ethnicity, region, number of medical
visits in the past year, ever hospitalized (yes/no), inﬂuenza immunization during previous inﬂuenza season (yes/no), additional
immunizations received on the same day as the inﬂuenza immunization (yes/no), and additional vaccines received 1–30 days prior
to the inﬂuenza immunization (yes/no). Region was based on
the location of the service member at the time of immunization. Regions were deﬁned as New England (Connecticut, Maine,
Massachusetts, New Hampshire, Vermont, Rhode Island), MidAtlantic (New Jersey, New York, Pennsylvania), East North Central
(Illinois, Indiana, Michigan, Ohio, Wisconsin), West North Central (Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota,
South Dakota), South Atlantic (Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, Washington, D.C.,
West Virginia), East South Central (Alabama, Kentucky, Mississippi, Tennessee), West South Central (Arkansas, Louisiana,
Oklahoma, Texas), Mountain (Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming), and Paciﬁc (Alaska,
California, Hawaii, Oregon, Washington). In addition, for the
non-recruits, separate analyses were conducted for each age category. SAS 9.1 (SAS Institute, Cary, NC, USA) was used for the
analysis.
This investigation was conducted for military public health
surveillance purposes and not research, therefore it did not undergo
institutional review board examination. No external funding was
received to conduct this investigation.

3. Results
3.1. Study population
For the 2005–2006 inﬂuenza season, we identiﬁed 701,753
non-recruits and 70,325 recruits. Among the non-recruits, 80.5%
received TIV and 19.5% received LAIV. Among the recruits, 71.1%
and 28.9% received TIV and LAIV, respectively. Although the TIV
and LAIV groups appear demographically similar for both the
non-recruit and recruit populations, the population demographic
differences were statistically signiﬁcant (Table 2). This mainly
reﬂects the large sample sizes of the populations and is not uncommon with studies of this size. However, of note, Soldiers made up
the majority of the LAIV group for both recruits and non-recruits,
where as the TIV group consisted of a similar percentage of Soldiers,
Airmen, and Sailors. In addition, among the recruits, LAIV recipients
were more likely to have had other immunizations administered in
the 1–30 days prior to their inﬂuenza immunization.
For the 2006–2007 inﬂuenza season, the cohort consisted of
757,091 non-recruits and 47,967 recruits. TIV and LAIV immunizations were more evenly distributed for the 2006–2007 season
with 49.2% and 63.4% of the non-recruits and recruits, respectively, receiving TIV. Consistent with the prior year, the LAIV group
consisted of a high percentage of Soldiers, the TIV group was
move evenly distributed with Soldiers, Airmen, Sailors and Marines,
and recruits receiving LAIV were more likely to have received
other immunizations in the 1–30 days prior to the inﬂuenza
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Table 3
Crude incidence rates of the non-recruit and recruit cohorts by demographic characteristics and immunization group, 2006–2007.
Characteristic

Non-recruits

Recruits

TIV

LAIV

TIV

LAIV

372,117
IR (95% CI)b

384,974
IR (95% CI)b

30,420
IR (95% CI)b

17,547
IR (95% CI)b

Age (years)
17–19
20–29
30–39
40–49

321 (307–336)
239 (235–243)
265 (259–271)
288 (278–298)

482 (468–496)
367 (363–371)
342 (336–348)
317 (307–326)

1846 (1796–1896)
2152 (2096–2208)
2478 (2166–2790)
2632 (1369–3896)

1363 (1314–1411)
1427 (1381–1474)
1860 (1683–2037)
2007 (1395–2619)

Sex
Male
Female

221 (218–223)
472 (461–482)

321 (318–325)
608 (597–618)

1898 (1858–1937)
2558 (2451–2664)

1301 (1266–1335)
1933 (1843–2023)

Race-ethnicitya
White
Black
Hispanic
Other

268 (265–272)
244 (237–251)
215 (207–224)
221 (210–231)

371 (367–375)
344 (336–351)
360 (349–371)
364 (351–378)

2005 (1961–2050)
1970 (1874–2065)
2012 (1873–2151)
2033 (1896–2170)

1464 (1423–1504)
1289 (1212–1366)
1479 (1364–1593)
1152 (1032–1272)

Service
Army
Air Force
Marine Corps
Navy

278 (272–284)
400 (393–406)
177 (171–184)
129 (125–133)

361 (356–365)
412 (407–418)
157 (149–165)
332 (320–344)

2504 (2422–2585)
2061 (2001–2121)
1145 (1084–1207)
2189 (2092–2286)

1616 (1576–1655)
711 (661–761)
2285 (1440–3129)
2988 (2418–3559)

Number of medical visits in previous year
0
197 (186–209)
<10
176 (172–179)
10–19
276 (270–282)
20+
477 (467–487)

393 (376–410)
383 (279–287)
367 (361–373)
558 (549–567)

2011 (1973–2048)
508 (283–733)
0.0
0.0

1421 (1388–1454)
912 (553–1271)
0.0
0.0

Ever hospitalized
No
Yes

231 (228–234)
359 (351–367)

351 (347–354)
418 (410–425)

N/A
N/A

N/A
N/A

Other immunization on same day
No
Yes

250 (246–253)
299 (290–309)

364 (361–368)
363 (355–371)

1521 (1371–1671)
2022 (1983–2060)

1069 (978–1160)
1456 (1421–1492)

Other immunizations in previous 1–30 days
No
256 (253–259)
Yes
253 (241–264)

362 (359–366)
383 (370–395)

2147 (2100–2195)
1721 (1661–1780)

1594 (1535–1653)
1326 (1286–1365)

Flu vaccine given in previous season
No
273 (269–277)
Yes
226 (221–231)

365 (360–371)
363 (359–367)

N/A
N/A

N/A
N/A

Total Cohort (N)

IR = incidence rate; CI = conﬁdence intervals; LAIV = live attenuated inﬂuenza vaccine; TIV = trivalent inﬂuenza vaccine.
a
Race-ethnicity was self-reported and categorized in the DMSS. “Other” included Asian/Paciﬁc Islander, American Indian/Alaska Native, and other.
b
Crude incidence rate per 1000 person-years.

immunization (Table 2). In addition, non-recruit LAIV recipients
were more likely than TIV recipients to have been vaccinated for
inﬂuenza during the previous inﬂuenza season.
3.2. ILI incidence
The crude incidence of ILIs stratiﬁed by various demographic and
service characteristics for the 2006–2007 inﬂuenza season is presented in Table 3. Overall, crude ILI incidence rates were 5–9 times
higher and 2–16 times higher comparing recruits to non-recruits
for TIV recipients and LAIV recipients, respectively. Females consistently had higher crude rates than males. Among non-recruits,
Airmen had the highest crude rates compared to the other services
regardless of vaccine group. Similar distributions were seen for the
2005–2006 season (Supplemental Table 1).
The timing of LAIV and TIV immunizations, distribution of ILI
events, distribution of CDC inﬂuenza conﬁrmed specimens, and distribution of censoring events for the continuous cohort for both
seasons are presented in Fig. 1 [31,32]. For the non-recruits, the
majority of inﬂuenza immunizations occurred by the end of December for both season. Since recruits were continuously entering
service throughout the inﬂuenza season, recruit immunizations

were more evenly distributed throughout each season. For both
seasons, peak ILI activity occurred during the ﬁrst 2 months of the
new year, although the 2006 season did have a slightly lower peak
during November and December. Censoring events for the both the
recruits and non-recruits were relatively evenly distributed through
each season.
3.2.1. Non-recruits
For the 2005–2006 continuous and November cohorts, the ILI
incidence per 1000 PY was 358.7 and 361.3 among LAIV recipients
and 271.6 and 291.5 for TIV recipients, respectively. For the intense
cohort, the ILI incidence was higher at 407.5 per 1000 PY and 315.2
per 1000 PY for LAIV and TIV immunized, respectively. Regardless of
the cohort, the ILI incidence among LAIV recipients was higher than
TIV recipients, with an adjusted IRR and 95% CI of 1.17 (1.14–1.20)
(Table 4).
Incidence rates for the 2006–2007 inﬂuenza season were similar to rates for the 2005–2006 season, however the magnitude of
the IRRs was greater (Table 4). The ILI incidence among LAIV recipients was higher than TIV recipients for all three analysis cohorts
for the 2006–2007 inﬂuenza season (adjusted IRR [95% CI]: 1.25
(1.23–1.27) to 1.33 (1.30–1.36)).
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Fig. 1. Timing and distribution of live attenuated (LAIV) and inactivated (TIV) inﬂuenza immunizations, incident inﬂuenza-like illnesses (ILIs), CDC ﬂu positive specimens,
and censoring events for non-recruits (A) and recruits (B) for the 2005–2006 and 2006–2007 inﬂuenza seasons.

For the age stratiﬁed analysis, IRRs decreased with increasing
age category. The highest IRRs were in the 17–19-year-old age category and lowest IRRs were in the 40–49-year-old age category for
both seasons and for all cohorts (Supplemental Table 2).

compared to TIV recipients for the 2005–2006 and 2006–2007 seasons, respectively.

3.2.2. Recruits
Table 5 combines the results of the 2005–2006 and 2006–2007
inﬂuenza seasons for the Army and Air Force recruits. Unlike the
non-recruit population, recruit LAIV recipients had statistically signiﬁcantly lower ILI incidence rates than TIV recipients. This ﬁnding
was consistent for both seasons and services and all cohorts (where
sample size was sufﬁcient to perform calculations) except for the
2006–2007 Air Force intense cohort, which did not reach statistical
signiﬁcance (IRR and 95% CI: 0.82 (0.62–1.09)). LAIV recipients had
a relative reduction in adjusted ILI incidence of 22–51% and 18–47%

Over two consecutive inﬂuenza seasons, we were able to follow large cohorts of service members to assess how well LAIV and
TIV protected against ILI. Our ﬁndings of greater protection from
ILI with LAIV compared to TIV for recruits and slightly greater protection with TIV compared to LAIV for non-recruits were initially
surprising. However, after consideration of these results we hypothesize that several factors may be contributing to this difference.
Among the recruit population, for both inﬂuenza seasons, we
found a signiﬁcant protective effect of LAIV against ILI compared
to TIV recipients. Two possible explanations for these ﬁnding are

4. Discussion

A.A. Eick et al. / Vaccine 27 (2009) 3568–3575
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Table 4
Crude and adjusted incidence rate ratios comparing LAIV to TIV among non-recruits by analytical cohort and inﬂuenza season.
Analysis cohort

2005–2006 Inﬂuenza season
ILI incidence
rate (per 1000
person-years)

2006–2007 Inﬂuenza season

Crude
incidence rate
ratio (95% CI)
LAIV vs. TIV

Adjusted
incidence rate
ratio (95% CI)a
LAIV vs. TIV

ILI incidence
rate (per 1000
person-years)

Crude
incidence rate
ratio (95% CI)
LAIV vs. TIV

Adjusted
incidence rate
ratio (95% CI)a
LAIV vs. TIV

Continuous cohort
LAIV recipients
TIV recipients

358.7
271.6

1.32 (1.30–1.34)
–

1.17 (1.15–1.18)
–

363.8
255.7

1.42 (1.40–1.44)
–

1.25 (1.23–1.27)
–

November cohort
LAIV recipients
TIV recipients

361.3
291.5

1.24 (1.21–1.27)
–

1.17 (1.14–1.20)
–

353.1
244.9

1.44 (1.41–1.48)
–

1.28 (1.24–1.31)
–

Intense cohort
LAIV recipients
TIV recipients

407.5
315.2

1.29 (1.26–1.33)
–

1.17 (1.14–1.20)
–

455.4
305.4

1.49 (1.47–1.53)
–

1.33 (1.30–1.36)
–

ILI, inﬂuenza-like illness; LAIV, live attenuated inﬂuenza vaccine; TIV, trivalent inﬂuenza vaccine; CI, conﬁdence intervals.
a
Adjusted for age, sex, race-ethnicity, service, region, ever hospitalized, number of medical visits in previous year, receipt of other immunizations on same day or 1–30
days prior to inﬂuenza immunization, and receipt of inﬂuenza immunization in previous inﬂuenza season.

that the recruit population has an intense burden of respiratory
disease compared to non-recruits and recruits may also have a different immune response to immunization compared to routinely
immunized non-recruits. Our recruit ﬁndings were similar to what
has been shown for studies comparing the vaccines in children.
Belshe et al. found a 54.9% reduction in the number of cultureconﬁrmed inﬂuenza cases among children 6–59 months for LAIV
compared to TIV recipients [1]. This effect is larger, but still similar
to our ﬁnding of approximately a 22–51% reduction in ILIs among
recruits. Although the recruit population is made up of people
17–42 years old, the majority of recruits (60–65%) were 20 years of
age or younger. This age group falls into the category with the lowest immunization rates in the United States, mostly likely because
they were not persons for whom annual immunization was recommended [26,27]. We suspect that the majority of recruits were

not immunized against inﬂuenza in the years prior to joining the
service and not at high risk for severe complications of inﬂuenza
disease. This may lead to some recruits having an immune system
that is relatively naive to inﬂuenza and to have a different immune
response compared to that of a more seasoned service member who
has received multiple annual inﬂuenza immunizations. Previous
studies have found LAIV to elicit a more robust immune response
and increased viral replication in unprimed subjects [33–36]. These
ﬁndings may explain the higher protection of LAIV compared to
TIV in recruits. With the new 2008 recommendation for annual
inﬂuenza immunization of children 5–18 years of age by the Advisory Committee on Immunization Practices, it will be important
to assess if prior immunization rates among recruits are increasing and whether these increases effect the robust ILI protection we
observed with LAIV [37].

Table 5
Crude and adjusted incidence rate ratios comparing LAIV and TIV among recruits by service and analytical cohort: 2005–2006 and 2006–2007 inﬂuenza seasons.
Analysis cohort

ILI incidence
rate (per 1000
person-years)

Crude
incidence rate
ratio (95% CI)
LAIV vs. TIV

Adjusted
incidence rate
ratio (95% CI)a
LAIV vs. TIV

Army

ILI incidence
rate (per 1000
person-years)

Crude
incidence rate
ratio (95% CI)
LAIV vs. TIV

Adjusted
incidence rate
ratio (95% CI)a
LAIV vs. TIV

0.56 (0.54–0.59)

0.64 (0.59–0.69)

Air force

2005–2006 Season
Continuous cohort
LAIV recipients
TIV recipients

1458.7
2735.2

0.53 (0.52–0.55)

0.53 (0.51–0.55)

1310.8
2325.9

November cohort
LAIV recipients
TIV recipients

1326.2
1406.0

0.94 (0.87–1.03)

0.78 (0.71–0.87)

Not applicable − counts
too small

Intense cohort
LAIV recipients
TIV recipients

1736.5
2158.7

0.80 (0.74–0.88)

0.74 (0.67–0.81)

701.7
2073.4

0.34 (0.30–0.39)

0.49 (0.41–0.59)

2006–2007 Season
Continuous cohort
LAIV recipients
TIV recipients

1615.7
2503.8

0.65 (0.62–0.67)

0.66 (0.63–0.69)

711.2
2061.1

0.35 (0.32–0.37)

0.53 (0.47–0.60)

November cohort
AIV recipients
TIV recipients

1668.2
2594.6

0.64 (0.58–0.71)

0.73 (0.60–0.89)

Not applicable − counts
too small

Intense cohort
LAIV recipients
TIV recipients

2004.3
2810.0

0.71 (0.61–0.83)

0.71 (0.58–0.86)

845.9
1072.3

0.79 (0.69–0.90)

0.82 (0.62–1.09)

LAIV, live attenuated inﬂuenza vaccine; TIV, trivalent inﬂuenza vaccine; ILI, inﬂuenza-like illness; CI, conﬁdence intervals.
a
Adjusted for age, sex, race-ethnicity, service, region, number of medical visits in previous year, and received other vaccines on same day or 1–30 days prior to inﬂuenza
vaccine.
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The intense burden of respiratory disease found in the recruit
setting may also play a role in the differences between recruits and
non-recruits. Crowded living conditions, stressful environments,
and the continuous entry of people from throughout the United
States into this population make this setting ideal for the spread
of respiratory pathogens [38,39]. Not surprisingly, we found rates
of ILIs to be 2–16 times higher among the recruits compared to
the non-recruits depending on the service, immunization group,
analysis cohort, and year of study. Previous studies of the recruit
population have reported signiﬁcant burden of respiratory disease
and outbreaks of disease, due primarily to adenovirus, inﬂuenza,
respiratory syncytial virus, and bacterial infections [14,18,40–43].
The high burden and mixing of a variety of respiratory pathogens
in this setting may alter the protective effect of vaccines. If
inﬂuenza plays a role in subsequent viral or bacterial infections,
then increased protection by LAIV may appear even greater in this
recruit setting. In addition, the broad case deﬁnition of ILI may
encompass these other acute respiratory pathogens.
The lower incidence of ILIs among non-recruit TIV recipients
compared to LAIV recipients was similar to most reports among the
general U.S. adult population. In a randomized, placebo-controlled
challenge study, Treanor et al. reported a higher protective efﬁcacy
of LAIV (85%) compared to TIV (71%) among adults but this difference lacked statistical signiﬁcance [6]. However, Nichol et al. found
LAIV to be statistically signiﬁcantly effective at preventing severe
febrile illnesses and febrile upper respiratory tract illnesses compared to placebo [8]. Another randomized, placebo-controlled trial
by Ohmit et al., found a higher absolute efﬁcacy for TIV for culture
or real-time PCR positive inﬂuenza (75% and 16%) compared to LAIV
(48% and 8%) for both the 2004–2005 and 2005–2006 inﬂuenza seasons among adults, but with overlapping conﬁdence intervals [5,7].
TIV has also been reported by Bridges et al. to be 86% efﬁcacious
against laboratory conﬁrmed inﬂuenza when compared to placebo
[9]. Although our ﬁndings are consistent with these previous
studies in adults, we were able to show statistically signiﬁcant dif´ = 0.05 level between LAIV and TIV protection from
ferences at an ␣
ILI. One possible explanation for this ﬁnding in our non-recruit population is high annual inﬂuenza immunization rates. Pre-existing
antibody from multiple years of inﬂuenza immunizations may be
playing a role in reducing the replication and antibody response to
LAIV [33,34,36,44–47]. However, our ﬁndings of an inverse relationship between LAIV to TIV IRRs and age, as shown in (supplemental
Table 2), is counter to the hypothesis that older age groups would
have received more inﬂuenza immunizations and therefore have
greater interference of pre-existing antibody with LAIV. One explanation of this ﬁnding is that older age may not directly correlate
with more years in military service or more inﬂuenza immunizations. However, we feel these ﬁndings really point out that the
interaction between LAIV and the immune system is multifaceted
and requires more detailed investigations of the innate and adaptive
immune responses to inﬂuenza immunizations.
An additional issue that could be playing a role in the difference between recruit and non-recruit ﬁndings may be differences
in circulating inﬂuenza strains. Although we did not have data to
speciﬁcally identify which strains were circulating in our populations, a previous study has reported differing vaccine effectiveness
for LAIV and TIV when looking at inﬂuenza A and B viruses separately. The study by Ohmit et al., although under-powered for the
strain speciﬁc assessment, reported a reduced protection of LAIV
against inﬂuenza B viruses [5]. Although inﬂuenza B viruses were
the minority, based on CDC data, they were present during both
seasons, typically later in the season [29,30]. If non-recruits were
more likely to be exposed to inﬂuenza B viruses than recruits, then
it may partially explain the differences we saw with LAIV.
The data used for this investigation present several limitations.
The principal limitation is our use of ICD-9 codes consistent with

ILI for the outcome of interest instead of laboratory conﬁrmed
inﬂuenza illness. By using this less speciﬁc case deﬁnition, it is
likely some of the events were caused by viral or bacterial respiratory pathogens other than inﬂuenza, and we overestimated the
true incidence of inﬂuenza. However, to minimize this risk, we
chose to use ICD-9 codes that had previously been shown in a very
similar population to be most associated with culture-conﬁrmed
inﬂuenza cases [29]. A beneﬁt of this methodology is that it allows
for assessment of the vaccines on a large population scale which
would be infeasible for a culture-conﬁrmed study. Additional weaknesses include a lack of smoking status, lack of knowledge about
the number of children in the household, and lack of medical and
immunization data prior to entry into military service. We were
unable to determine whether recruits were immunized or infected
with inﬂuenza in the year prior to entry into the service or to
control for potential confounders such as past medical history or
medical care usage patterns. However, in order to enter military
service, applicants must meet certain physical and medical eligibility standards, which should decrease the likelihood of inclusion of
recruits with signiﬁcant medical conditions that would put them at
higher risk for ILI [48,49]. Selection bias may have occurred for the
November cohort, but was necessary to be able to control for differences in the timing of LAIV and TIV administration. Using the CDC
national inﬂuenza data to determine the windows for the intense
cohorts may not accurately account for region and military differences in peak inﬂuenza activity. Although military speciﬁc data
were not available, we did determine region speciﬁc windows for
peak inﬂuenza activity using the CDC regional data and performed
regional intense cohort analyses. The ﬁndings from these regional
analyses were similar to the overall intense cohorts presented here
(data not shown). The possibility for residual confounding and/or
unmeasured confounding is also a limitation to the study.
Our results support continued immunization and preferential
use of LAIV for the recruit population. Among adults regularly
immunized against inﬂuenza and in a non-recruit setting, our
ﬁndings of a slightly higher effectiveness with TIV favor immunization with this vaccine. Consideration of these ﬁndings should
be made when developing inﬂuenza immunization policies. This
study was strengthened by the consistency of ﬁndings using multiple study cohorts and over multiple inﬂuenza seasons. Additional
studies of this nature are needed among adults to see if these ﬁndings are generalizable to the general U.S. population. In addition,
investigation of the role of annual inﬂuenza immunizations in the
adult population on the immunogenicity and viral replication of
LAIV are needed. Continued assessment of these vaccines in subsequent inﬂuenza seasons is essential, especially during years of
sub-optimal vaccine strain match and more signiﬁcant seasons to
assess how well these vaccines perform.
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